Biosearch Technologies, Inc.

Biosearch Technologies, Inc. (LGC Biosearch Technologies Division), a foreign-owned manufacturer of oligonucleotide-based molecular biology tools and diagnostic reagents headquartered in Petaluma, California, operates as a prime contractor selling laboratory supplies, PCR kits, primer probes, and diagnostic assay components to federal health agencies on a full-and-open competitive basis. The vendor holds no SBA certifications and does not compete under set-asides.

Biosearch's federal footprint centers on diagnostic and research-grade laboratory reagents, particularly molecular biology components for pathogen detection and disease surveillance. The vendor manufactures oligonucleotide primers, dual-labeled probes, PCR testing kits, and Good Manufacturing Practice (GMP) diagnostic assay kits. Representative prime work includes a $763,453 definitive contract with the CDC for GMP manufacturing of FluSC2 Multiplex diagnostic kits (awarded September 2024), a $757,634 sole-source definitive contract for SARS-CoV-2 influenza multiplex oligonucleotide primers and probes (April 2023), and a $249,997 CDC purchase order for PCR testing kits (November 2024). The vendor also supplies specialized probe products to the Department of the Navy's Bureau of Medicine and Surgery, including dual-labeled probe 5' Quasar variants, and has provided smFISH probes to the National Cancer Institute.

Customer concentration is heavily skewed to the Department of Health and Human Services. The CDC (split across Pittsburgh and Office of Acquisition Services locations) accounts for approximately 72% of awards by count—81 awards carrying $317.9 million in combined potential value—while the Bureau of Medicine and Surgery represents 21 awards valued at $460 thousand. The Air Force Materiel Command Research Laboratory has placed 17 awards worth $5.1 million. The gap between award volume and dollar concentration reflects the CDC's dominant role: the CDC Office of Acquisition Services holds only 34 awards but anchors nearly 82% of the vendor's total potential value at $272.4 million, signaling concentration in high-dollar blanket purchase agreements rather than transactional purchase orders.

Biosearch operates under several CDC vehicle structures. The Blanket Purchase Agreement 75D30119A04957 carries 15 task orders valued at $4.2 million, and the vendor places task orders against multiple CDC indefinite delivery contracts (HHSD200200826694I with 12 task orders for $3.3 million; HHSD200201357252I with 8 task orders for $3.1 million). The Air Force Indefinite Delivery Contract FA860113D0009 accounts for 19 task orders worth $851 thousand. The source references a $19 million blanket purchase agreement with the CDC that anchors the vendor's federal supply strategy for primer probes, assay kits, and oligonucleotides delivered to state public health laboratories under the Laboratory Response Network.

Activity has contracted markedly in recent years: the vendor recorded three awards in 2023, four in 2024, and only one each in 2025, 2026, and 2027. Combined potential value across all 180 awards reaches $332.2 million, but only $26.3 million (8%) has been obligated. Obligations suggest smaller per-order dollar flows than the ceiling structure implies; the recent awards detailed in the source (purchase orders and BPA calls) range from roughly $13,000 to $763,000, indicating transactional or call-order usage of larger standing vehicles rather than flat upfront commitments. The recompete cliff is minimal—only two awards (combined $93 thousand) complete within the next twenty-four months, reducing near-term competitive recompete exposure. The vendor operates as a 100% prime contractor with no subcontract footprint, performing manufacturing and supply fulfillment at its Petaluma, California facility and at performance locations including Atlanta, Georgia and Peru. NAICS concentration spans oligonucleotide and diagnostic manufacturing (All Other Basic Organic Chemical Manufacturing, Biological Product Manufacturing, and In-Vitro Diagnostic Substance Manufacturing); PSC coding emphasizes Laboratory Equipment and Supplies and In Vitro Diagnostic Substances.